预约演示

更新于：2025-03-20

AD-010

更新于：2025-03-20

概要

概要

基本信息

药物类型

蛋白类药物

别名

blood clotting regulatory protein(Jiangsu Aidea Pharmaceutical)、coagulation regulatory protein(Jiangsu Aidea Pharmaceutical)、natural thrombomodulin(Jiangsu Aidea Pharmaceutical)

+ [4]

靶点

THBD

作用方式

刺激剂

作用机制

THBD刺激剂(血栓调节蛋白刺激剂)

治疗领域

血液及淋巴系统疾病其他疾病

在研适应症

弥散性血管内凝血炎症

非在研适应症-

原研机构

江苏艾迪药业股份有限公司

在研机构

江苏艾迪药业股份有限公司

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)临床前

特殊审评-

关联

项与 AD-010 相关的临床试验

JPRN-UMIN000012590

/ RecruitingN/AIIT

The retrospective study of treatment by thrombomodulin for acute exacerbations of idiopathic pulmonary fibrosis, acute respiratory distress sydmrome - The treatment of thrombomodulin for acute respiratory failure

开始日期2010-04-01

申办/合作机构

Chiba University

100 项与 AD-010 相关的临床结果

登录后查看更多信息

100 项与 AD-010 相关的转化医学

登录后查看更多信息

100 项与 AD-010 相关的专利（医药）

登录后查看更多信息

222

项与 AD-010 相关的文献（医药）

2025-01-01·Proceedings of the Japan Academy, Series B

Thrombomodulin: A key regulator of intravascular blood coagulation, fibrinolysis, and inflammation, and a treatment for disseminated intravascular coagulation

Article

作者: SUZUKI, Koji

Thrombomodulin (TM) is an important regulator of intravascular blood coagulation and inflammation. TM inhibits the procoagulant and proinflammatory activities of thrombin and promotes the thrombin-induced activation of protein C (PC) bound to the endothelial PC receptor (EPCR). Activated PC (APC) inactivates coagulation factors Va and VIIIa, thereby inhibiting blood clotting. Additionally, APC bound to EPCR exerts anti-inflammatory and cytoprotective effects on vascular endothelial cells. TM also protects cells in blood vessels from inflammation caused by pathogen-associated and damaged cell-associated molecules. Excessive anticoagulant, anti-inflammatory, and tissue regenerative effects in the TM-PC pathway are controlled by PC inhibitor. A recombinant TM drug (TMα), a soluble form of natural TM developed from the cloned human TM gene, has been evaluated for efficacy in many clinical trials and approved as a treatment for disseminated intravascular coagulation (DIC) caused by diseases such as sepsis, solid tumors, hematopoietic tumors, and trauma. It is currently widely used to treat DIC in Japan.

2024-09-16·Future Medicinal Chemistry

Molecular docking, derivatization, characterization and biological assays of amantadine

Article

作者: Ahmad, Irshad ; Akram, Muhammad Toseef ; Awan, Breena ; Khan, Muhammad Rizwan ; Khan, Mohsin Abbas ; Ullah, Farhat ; Yasmeen, Zarmeena

Background: Derivatization has been tremendously utilized in the field of drug discovery for optimizing the pharmacological properties and improving safety, efficacy and selectivity.Methodology: Schiff's bases (AD1-AD11) are synthesized through amantadine condensation with different aldehydes and ketones. Fourier transform infrared, ¹H NMR, ¹³C NMR, TLC, liquid chromatography mass spectrometry analysis, in silico studies, molecular docking and antiviral activity through hemagglutinin test were performed for evaluation of new compounds.Results: AD2, 3 and 9-11 showed greater antiviral activity than the parent drug. Among all derivatives, AD2 and AD3 exhibited good potential against α-amylase while AD7 and AD10 showed stronger inhibition against α-glucosidase.Conclusion: So, it is concluded that the most potent derivatives can be used as lead compounds in novel drug design of antiviral antidiabetic agents.

2024-08-28·Cureus

Iliopsoas Abscess, Spondylodiscitis, Septic Pulmonary Embolism, and Symmetrical Peripheral Gangrene by Hypermucoviscous Klebsiella pneumoniae

Article

作者: Hayashi, Koji ; Hayashi, Maho ; Hamada, Hina ; Morikawa, Yukie ; Shirasaki, Akihisa ; Yamamoto, Chie

Hypermucoviscous Klebsiella pneumoniae (hmKP) is a bacterium known to cause lesions, including abscesses, in various organs. Unlike typical Klebsiella pneumoniae, hmKP can yield a positive string test in culture specimens. Infections caused by hmKP often become severe and are associated with a poor prognosis. In this report, we describe a case of iliopsoas abscess, spondylodiscitis, septic pulmonary embolism, and symmetrical peripheral gangrene (SPG) caused by hmKP. The patient received non-invasive positive-pressure ventilation, hemodialysis, platelet transfusions, fresh frozen plasma, thrombomodulin, and intensive antibiotic therapy including rifampicin. The patient underwent 148 days of antibiotic therapy and achieved a good outcome.

100 项与 AD-010 相关的药物交易

登录后查看更多信息